Key Stats for TNGX Stock
- Price Change for TNGX stock: +36.3%
- $TNGX Share Price as of March 05: $17
- 52-Week High: $17
- $TNGX Stock Price Target: $16
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Tango Therapeutics (TNGX) stock jumped 36.3% on March 5, closing at $16.83 and reaching its highest level in the past year. The rally followed a combination of new partnership news and updated financial results that highlighted growing collaboration revenue. Investors also reacted to developments in the company’s oncology drug pipeline.
One of the biggest catalysts was a clinical collaboration with Erasca to evaluate a combination therapy for cancers with MTAP deletions. The companies plan to test Erasca’s ERAS-0015 with Tango’s investigational PRMT5 inhibitor vopimetostat. The early-stage study will focus on pancreatic cancer and RAS-mutant non-small cell lung cancer.
Tango also reported full-year 2025 results, which showed strong growth in collaboration revenue. Revenue reached $62.4 million, up 108% year over year due to partnerships supporting its drug discovery programs. Despite that growth, the company still reported a net loss of about $101.6 million, reflecting heavy research and development spending.
Management also spent the week presenting at major healthcare conferences, including the TD Cowen Health Care Conference on March 4. Additional presentations scheduled for March include the Barclays Global Healthcare Conference and the Leerink Global Healthcare Conference. These events often drive biotech momentum as investors receive updates on clinical progress and future milestones.
See analysts’ growth forecasts and price targets for TNGX stock (It’s free!) >>>
What the Market Is Telling Us About TNGX Stock
The strong move in TNGX shares reflects growing investor interest in precision oncology. Tango Therapeutics focuses on synthetic lethality, a drug discovery strategy targeting genetic weaknesses in cancer cells. The company’s pipeline focuses particularly on tumors with MTAP deletions, which occur in several difficult-to-treat cancers.
Financial results also show the company’s business model in action. Tango generated $62.4 million in revenue in 2025, up from $42.1 million in 2024. However, heavy R&D spending of $132.2 million kept the company unprofitable, producing an operating margin of about (178.4%) and free cash flow of roughly ($139.9 million) over the last year.
The balance sheet remains relatively strong for a clinical-stage biotech company. Tango ended the latest period with about $343 million in cash and short-term investments, while total debt stood at only $33.6 million. That leaves the company with net cash of about $309.6 million, providing funding for ongoing clinical trials.
Wall Street analysts currently have an average price target of $15.89 for the stock, which is slightly below the recent $16.83 closing price. Analyst targets range from $13 to $20, reflecting uncertainty about the timeline and success of future drug trials.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Long-Term Valuation Perspective
While analyst price targets focus on the near term, long-term valuation models often take a broader view of potential growth. In the model provided, the mid-case scenario estimates a future price of $59.45 by 2030.
Based on that scenario, the model suggests 253.2% total potential return over the next 4.8 years, which would translate to roughly 29.9% annualized returns. That estimate assumes strong long-term revenue growth driven by successful clinical development.
However, those projections depend heavily on clinical outcomes and regulatory progress. Biotech valuations can change quickly depending on trial results or partnership announcements. Investors typically treat these models as scenarios rather than guarantees.
Because Tango remains a clinical-stage biotechnology company, the investment thesis largely depends on future drug approvals rather than current profitability. That means the stock can remain volatile as new data from clinical trials emerges.
Should You Invest in Tango Therapeutics, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up TNGX, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track TNGX alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Tango Therapeutics stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
